<SEC-DOCUMENT>0001193125-16-492226.txt : 20160304
<SEC-HEADER>0001193125-16-492226.hdr.sgml : 20160304
<ACCEPTANCE-DATETIME>20160304060734
ACCESSION NUMBER:		0001193125-16-492226
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160304
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160304
DATE AS OF CHANGE:		20160304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		161483509

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d139046d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March 4, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARDELYX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36485</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-1303944</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>34175 Ardenwood Blvd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fremont, CA 94555 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (510) 745-1700 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 4, 2016, Ardelyx, Inc. (the
&#147;Company&#148;) announced its financial results for the fourth quarter and year ended December&nbsp;31, 2015. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on
Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished under this Item 2.02 shall not be considered &#147;filed&#148; under the Securities Exchange Act of 1934, as amended,
nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under&nbsp;the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such
information is to be considered &#147;filed&#148; or incorporated by reference therein. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Ardelyx, Inc.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:&nbsp;March 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ARDELYX, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Kaufmann</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Kaufmann</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Ardelyx, Inc.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d139046dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g139046ex99_1p1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">34175 Ardenwood Blvd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fremont, CA 94555</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(510) 745-1700 &#150; Tele</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(510) 745-0493 &#150; Fax</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.ardelyx.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx Reports Fourth Quarter and Full-Year 2015 Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Three Late-Stage Clinical Trials for Tenapanor Initiated in 4Q2015 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>RDX022 PD Study Results Support Pivotal Phase 3 Clinical Trial Plans for Hyperkalemia in 2H2016 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Conference Call and Webcast Today at 8:00 a.m. ET </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FREMONT, Calif., March 4, 2016 /PRNewswire/ &#151;&nbsp;Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal
and cardio-renal diseases, today announced financial results for the fourth quarter and full-year ended December&nbsp;31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;2015 was an
exceptional year for Ardelyx, highlighted by the advancement of our clinical programs and other corporate achievements,&#148; said Mike Raab, President and Chief Executive Officer of Ardelyx. &#147;We regained worldwide rights to our lead product
candidate, tenapanor, from AstraZeneca, and accelerated its development in multiple indications. We initiated two Phase 3 clinical trials for tenapanor in IBS-C and a second Phase 2b clinical trial for tenapanor in hyperphosphatemia. We also
completed a study evaluating the pharmacodynamic activity of RDX022 in hyperkalemia, the positive results of which support our plan to initiate a pivotal Phase 3 clinical trial in the second half of 2016. We remain committed to advancing our
late-stage assets and rounding out our pipeline with the development of promising preclinical assets such as RDX009, for which we intend to file an IND in the second half of 2016.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Clinical &amp; Corporate Developments </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In December, Ardelyx initiated the second of two planned Phase 3 clinical trials evaluating tenapanor for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). The trial&#146;s endpoints are
similar to those of the first Phase 3 clinical trial, which was initiated in October, including a 12-week primary endpoint. Additionally, the study will evaluate tenapanor versus placebo at 13 of 26 weeks along with an open-label extension.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In December, the Company also commenced a second Phase 2b clinical trial evaluating dosing regimens of tenapanor in end-stage renal disease (ESRD) patients with hyperphosphatemia. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In October, Ardelyx initiated an open-label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in 60 healthy adult volunteers. Positive results from the PD study (announced in January&nbsp;2016)
demonstrated RDX022&#146;s ability to bind potassium effectively in the gastrointestinal tract. In this study, RDX022 was generally well-tolerated at all doses administered up to 27.5 g/day. These findings support Ardelyx&#146;s plans to proceed
with a Phase 3 clinical program. Ardelyx is pursuing regulatory approval for RDX022 using the 505(b)(2) regulatory pathway. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ardelyx further strengthened its senior leadership team with the appointment in January&nbsp;2016 of Paul Korner, MD, MBA, as Executive Vice President and Chief Medical Officer. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In January&nbsp;2016, Ardelyx raised net proceeds of approximately $80.4 million in an underwritten follow-on public offering of its common stock. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upcoming Clinical Milestones </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Results from the second Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia in ESRD patients are expected in the second half of 2016 </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Initiation of a pivotal Phase 3 clinical trial to evaluate RDX022 for the treatment of hyperkalemia is currently planned in the second half of 2016 </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Planned IND submission in the second half of 2016 for RDX009, a TGR5 agonist that stimulates local secretion of GLP-1 and GLP-2 in the gastrointestinal tract </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Results from two Phase 3 clinical trials evaluating tenapanor for the treatment of IBS-C are expected in 2017 </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fourth Quarter and Year Ended December&nbsp;31, 2015 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net loss for the year ended December&nbsp;31, 2015 was $29.6 million, or $1.29 per basic and diluted share, compared to a net loss of $3.2 million, or $0.31
per basic and diluted share for the year ended December&nbsp;31, 2014. Net loss for the fourth quarter of 2015 was $17.0 million, or $0.65 per basic and diluted share, compared to a net loss of $4.0 million, or $0.21 per basic and diluted share for
the fourth quarter of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total revenue is comprised of licensing revenue and collaborative development revenue. Licensing revenue increased to $21.6
million for the year ended December&nbsp;31, 2015 from $18.4 million for the year ended December&nbsp;31, 2014. The increase primarily reflects the impact of the recognition of the remaining deferred revenue balance related to the AstraZeneca
license agreement of $43.1 million during the three months ended June&nbsp;30, 2015, which was recognized as a result of the termination of the license agreement with AstraZeneca in June&nbsp;2015. This amount was primarily offset by an aggregate of
$25.0 million in upfront payments made to AstraZeneca in connection with the termination of the AstraZeneca agreement. Licensing revenue for the fourth quarter of 2015 decreased to zero from $3.9 million for the fourth quarter of 2014 because of the
termination of the AstraZeneca agreement in June&nbsp;2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborative development revenue is comprised of development expenses that were reimbursable
to Ardelyx by AstraZeneca. Collaborative development revenue for the year ended December&nbsp;31, 2015 decreased to $2.4 million from $13.2 million for the year ended December&nbsp;31, 2014. Collaborative development revenue for the fourth quarter
of 2015 decreased to zero from $2.5 million for the fourth quarter of 2014. The decrease in both the full year and fourth quarter was attributable to the termination of the AstraZeneca agreement in June&nbsp;2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense for the year ended December&nbsp;31, 2015 increased to $39.9 million from $25.9 million for the year ended December&nbsp;31,
2014. The change was primarily due to the $7.3 million in expenses incurred for the tenapanor clinical trial material purchased from AstraZeneca as well as an increase of $6.7 million in expenses incurred for clinical development activities
associated with tenapanor and RDX022, and manufacturing process development for RDX022. Research and development expense for the fourth quarter of 2015 increased to $12.8 million from $7.4 million for the fourth quarter of 2014. The increase was
driven by an increase of $5.4 million in expenses incurred primarily for clinical development activities associated with tenapanor and RDX022, and manufacturing process development for RDX022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 6 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense was $13.5 million for the year ended December&nbsp;31, 2015 compared to $7.3
million for the year ended December&nbsp;31, 2014. General and administrative expense was $4.1 million for the fourth quarter of 2015 as compared to $2.9 million for fourth quarter of 2014. The increase in both the full year and the fourth quarter
was primarily due to an increase in professional services fees, personnel and public company costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents were $107.0 million as of
December&nbsp;31, 2015 compared with $107.3 million as of December&nbsp;31, 2014 primarily as a result of the private placement completed in June&nbsp;2015 that yielded approximately $74.3 million in net proceeds, offset by $3.5 million of capital
equipment purchases and $71.8 million in cash required for operating activities including the $25.0 million paid to AstraZeneca in connection with the termination of the license agreement in June&nbsp;2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;13, 2016, we completed the sale and issuance of an aggregate of 8,625,000 shares of our Common Stock in an underwritten public offering. We
received net proceeds from the offering of approximately $80.4 million, after deducting the Underwriters&#146; discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call &amp; Webcast Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ardelyx
management will host a live conference call and webcast today at 8:00 a.m. ET&nbsp;to discuss the financial results for the fourth quarter and year ended December&nbsp;31, 2015. The live webcast and a replay may be accessed by visiting the Investor
Relations section of the Ardelyx website at ir.ardelyx.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please connect to the Company&#146;s website at least 15 minutes prior to the live webcast to
ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-855-296-9612 (US) or 920-663-6277 (International) to listen to the live conference call. The conference ID number for the live call
is 58231765. Please dial in approximately 10 minutes prior to the call. An archived webcast replay will be available on the Company&#146;s website until March&nbsp;18, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ardelyx, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ardelyx is a clinical-stage
biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal
diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor,
which it is evaluating for the treatment of constipation-predominant irritable bowel syndrome, or IBS-C, and management of hyperphosphatemia in patients with end stage renal disease. In addition to tenapanor, Ardelyx is developing RDX022, a
non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients. Ardelyx is also advancing several research programs focused in gastrointestinal and cardio-renal diseases. Ardelyx is located in
Fremont, California. For more information, please visit Ardelyx&#146;s website at www.ardelyx.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 6 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements
reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for tenapanor in treating IBS-C and hyperphosphatemia in end stage renal disease
patients, Ardelyx&#146;s future development plans for tenapanor and the timing thereof,&nbsp;the expected timing for the receipt of the results for the Phase 3 clinical trials in IBS-C, the expected timing for the receipt of the results for the
Phase 2b hyperphosphatemia clinical trial, the potential for RDX022 in treating hyperkalemia in kidney and heart disease patients, Ardelyx&#146;s future development plans for RDX022 and the timing thereof, the expected timing for the initiation of
the Phase 3 clinical trial for RDX022, the expected timing for the filing of an IND for RDX009, and the potential of Ardelyx&#146;s drug discovery and design platform. Such forward-looking statements involve substantial risks and uncertainties that
could cause the development of tenapanor, RDX022, or Ardelyx&#146;s&nbsp;future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in research and the clinical development process and&nbsp;the uncertainties in the manufacture of clinical trial material, including process development, scale up and tech transfer of manufacturing
processes.&nbsp;Ardelyx&nbsp;undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Ardelyx&#146;s business in general, please refer to Ardelyx&#146;s Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on March 4, 2016, and its future current
and periodic reports to be filed with the Securities and Exchange Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 6 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Derived from the audited financial statements included on Form 10-K for the year ended December&nbsp;31, 2014. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 6 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Twelve Months Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaborative development revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Provision for) benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,621</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,958,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,473,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,892,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,248,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Derived from the audited financial statements included on Form 10-K for the year ended December&nbsp;31, 2014. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor and Media Contact: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Kaufmann </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mkaufmann@ardelyx.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">510-745-1751 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Investors: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bill Slattery, Jr. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Burns McClellan on behalf of Ardelyx Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">bslattery@burnsmc.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">212-213-0006 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOURCE Ardelyx, Inc. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 of 6 Pages </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g139046ex99_1p1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g139046ex99_1p1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0 $: P$1  (1 0,1 ?_$ -P   (!! ,! 0
M      D*" $$!PL#!08  @$  @(" P$             !P@#!@0%  () 1
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M(1N-M[]8O;_RP1C].V#TN!5%DY^E*FHX*V6^F3<B(('< F;R"+F IS B94
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MB81,)&\)-UZ!LM7;GV,83'0&5?)%[O FVW0HZKVU=M,VKJ/6O-H(+H*AW93
MUS(YCC/@([7"J<J+0TWJG+MGRB=?MLZ90[%SBN4Q:F[!Y9:5AB9EJ&D]!)8&
MTPZFH^'EW\:14#"H[2B%5=U/O(@8>T0WUH?,X\_2[3;71JF%GOR.(D 1@.9P
ME&_Z<6]LW0NO"1EA,0]VV3;E X) F7YB@<"E#Q*0I"[@'V$( !^ -(A0!;K
M6XX5NG$]Z<I\#CA!Y*%(6?#&D&7#.+KM#[2_W.LSPNU7MCY^UYQQJ )B&#Q*
M8H@8!#H("'7Q\0'4;\PH)253/*.BDN)'=E.%@/= !MQMXWB&P@;,TZ(B7;8=
MZ>?J(AXB( &F5\LC 1NVITS*_EL>>2X%W4<NFVLAS+6KZA QO;4_^_*\_@P%
M9_XV5G1-\PH/^26@?^L5_21%/Z:?XIZS]1A[P"!L(;>.^X"'COX_NZ1]Q/CX
M*P A@D(#9)'$QC;+N,JAEW&]OQA=XI&5J-[@Y"LV!@H@10JT;*-%6BQMC@(%
M5;E/YB9P^8BA"F#J&LJV5%1::YJXTSA0NG6%CMTG+U_5&)<+<Q=*55.\!+/'
MB1&LHYA\9K=P^Y&9(P1;2NA"GRRAJW*B51!&PT]VH5[5IMJX.4QSA(1G:!U"
MF$2.4C$$?EUZ2[-W?3[HVH*U>EQ=4WH4D'44?R@)RRXRSA8[Y1JLMX+8[IU8
M X$^B'=O1EYR->3G#:/#(EF;DR-QZCDZ=DAY(+II+.:_"17GP-U=]R@@+21K
MR >>KX Z:K==A#=)NJ^S#LK=)H*)!?IZQV:"@:DS5A(E,P#ASXP;]C[@-5;%
ML51"5,)EWL#AZ83I]3#F'(<SN6F1<JE=JEH4)(+5#%T<8_FE842ON%6[1\DF
M ;&7FW157RP;  F==H[^673?]*-DTNT=J-LJ4A534-AQ1P[ND:R#+*64"'<]
MS<O5Q<:4?V87(8\ J&N/03X)!QSXYGSS?H8[;+_(!A'R":3YL/Z0K.,$ !>L
MPY"CV_3N)_N+(N"B #N9,!ZETI777?SM[W!^1T+@<9864DH.H!6"3.60 X_"
M"]LJP4U-0IJ2 7"!RC&'N&.#8Y>PU&<M*'# M?\ ";,S"^MVS8ZKJ<QBX="/
MU2H(E ZJE-DG0N.X0'9JJIL.Q=;WH%NY6V+\+$XX/E*XA)).2B>)G("1/+*-
M;O\ V^W6-*KD)FZ1PQR$LH7(]*+F:ZX6\N:7<)*152QC?%FV.<I-S* 5 :[/
MND@83RA1+^:<UB643=E ?_IR+%$0[NK+];-IHW)MY:*9!^8HF?%;(']HK]%)
M_$>^<!,X'E QVO<WK3<VFU$I/B2ED3ZN,-7^N5S<)QPX@N*/2+&4N3N1Z"M5
MK2\:[*JM&T!9LDO<;.V.0Y1(FO$N2LD50V*)W(F(/<&E Z0]/:N_;K75/J_Y
M5A4U%0D 1D)DR!!Q]G."UO>\%BRI<84/%6,@<?8,83KX"<2K+S1Y-X[PK$(N
MT(%W(IS609<J1C_H3'L(=!2;?+' 0(@N[:D(@TWV/]2X3WZ=VG+WQNW]WEC7
M5H4E52ICPT)F-1!F 0)S(,SB,Y& W8[2[7W5"W02E0!.'IC9@4>CUK']2K%,
MJ<8VAJW4X.&KT!%M4B)),(F&:ILV#8I"%*&Z2*8;CXB81$>HZ\WGU55QOC]_
MK%E3SY),\,222??#,T++=OI4,MIPE+VQ[C4\9<?#U 0^W7(Y%@X$"IGZ[ 4@
M%$1'MVWV =S?D@/V_#QUU=0'%(2>*OM$8ZW/VJE<A&M7]73/YN1?/[/MM;O1
M=UVJV4,8U+\YYB*<-140AS?3B F*!7DBDNN8 '83JCKT*Z,[:-NV86WI>([H
M=])2%$_TH73>MQ%=7N4Z>"I0V-[>?C\;$G B/R#)LOIY[/MSE\@+G4(=%0]:
MCE/U<JR9^XH'.)6\<LN00^4Y'!1^&E9Z];F7N#=X*"%-40"1+/+&?NE!:V#1
M&W61+JL)QV7N!\!#F#@'9+E'Q_U5BP/:83);%9-(#KD@55#0-G22[0%4WF,9
M$IE/R \H#C]W6/T"W.=O[R^<=DEJK!1/V2'N,1=0*!559%*3C(0HGZ3N?PXZ
M<^N/=[6?@TKTW:D,>6PQEO);J5[(*80!SN3#L!D6+]VW<[#T R'X--AU@VS^
M;;-6TUBM)4][0 #[H$.QZU-IKD)5@%JTQLN4BE$0[/N]>T0#8!#;IL = #;8
M->=#5/X3SB3@289'4''4+&1B-O*+ES@WB#BZ5RIG2XH5&MM5#L(Y#RQ7G;)+
MF(84(>LQ)!!W*2*X[!\@ FD!@,H8A>NK)MG;5SW)6BAM#94\H\C+.4S++&,6
M]7=BU->(LXRA8K*ON@[ ,ZZ3P=QDBPKWG*)M9;)5M=!,/VZ!Q33>*Q-=:D;L
MRK@'<4@NE3%#[P:9RU^5BYNT*;C>ZKY9"@!,?I'(=XC.4"^JZBD*(;(T3C$P
M>Y]Y-=QM^.F%OAL;]-W3<VP>)@^JZ"&MA_I?MO"['^9_6C%_>.[V1#+FAZXG
M*GF3C"4PT]@:7B6A67Y+@VH)YL9>ULT^U8D+)RTH^=*$A579$SJ(H)HF6$@@
MH<2#VZMFT_+W;-M7-NY./>/(S"R!Z)B6<\L9QJK_ +V?KZ)+2,R/MB*WIE\9
M[#RHYHX3QW%Q:[V!A+?$WN_/BI'49P=1IDBA+OG+]5+<B17CIHFV1W'M454
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M*H ?8I1UZ.]*=X+WUM]#MPD33)[WJP^V%JWG:W+=<A44T_F$F:3VQ&[,N?\
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MG:/M1."OT\7KM$\LQ[#!\3"(=P@&X@(;!]ORZ#: "TV#E,1=::1?<GEA]4?
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MWC('*0S('OBG,)JKO<OE$$Z9Y@3/L@L<=[?;U)I%FW>!1,;M0<((K?3.LFP
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M%5IIEHIH0P6VO2,$2S0$?:8 LNV49FE:W,^::(GV(*=H.8]TFD8Y%";E.)!
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MV3>1\HT,*2Z(]1*._P H@!@=K=6UF=^[?TW-25(4,<OX8$%LO-5MQT3201#
M,=[GCDTT:(INN/.&7;P$TRNET):WLD%54DRI>8BU,Z<&2(<A0Z"J?[.FW5>W
M?+/M5D!2:QUE2YDR$YX]C9RB^)ZH5*D#4D#"+[]J#Y)_T<,._P#Y^W?]+J'_
M $V[8_[D]^J?_P"4??WG5'(>R.$?<_<DS )3<;L-& 2COW3UM$1#J/4?,W$
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MJTU;I*E$2S5B9B4C*?'*+!:M^WJ@2$$'PP !/E[8(F3W/?)8A2]_';#:QP*
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M39_$5SPQR  Q].$7';>P5T)UU20KLE+XPV%#5^/@6+2-BF[=A&L&K9E'QS-
MC9DP9M&R;5LT:-D]DVS9!%(I2$( %(4H%#H&EL>6[45/S#AF29]LSGCZ8*M,
MPFG3),1<YW\>?YTW$S-F!42LS2^0:6_CJPJ^-Y35K;61D9:KO%5]A^G(VFX]
M$PJ?D@ ZWVT=QIVEO"@W$ZN5.RZ=2)$ZTE*DJ (R,C,8'&,6\4)N5&ME [\C
M*$V<9^@]ZG6,\@4/(\%5L9(3U%M5>M4>9/)D24 =0TNWE"IE-Y9![1%$"#O]
MX@"'QTW-PZZ[!NNWW[;6I634+*A.<D@RP^[CRF"( Z-CWVDN9J6YK3.<@"/M
MC[*WH(>I!?<D9&N[>DXR01N5SM5H21-DJ* 4"V"8>R@)GV;[%\L76WV!KO:.
MONSK?3%ED*<_Y<- !4LDZ0?NGV1L$[&O%74^,KN=Z>(//TPZ?Q$QS9L2<9\$
M8MN2+1O:Z#BZH5:Q(L72;]DE,0L2W:/TFKQ+\VZ0(N00*H&P&#2;;@J55EYJ
M:VED&WWE+$Q.0*B9<,<<^R#39Z-VVT**9T3*4@3]L2.,@8V^YB[#X!V^'X]:
M==+2NG6Z@%SG&6E+WB3<5-KE&-<C8;QWEZK3-(RE3JU?JA.HJ(R5=L\2A+1S
M@#E[05!)UWBW<I_X-5(2*IB.Y3!J:U+J-O5INFWG7*:YE4]85D<L )<!QCI4
MT-!4@ZFQ,\Y?"%?><OMMJ]-&E;WPEMZ%4?.#J.%,-WQXY7K(JNC "@5.W'%T
M_B4P$PE*U=%51#8/S@!L(,UM7S&W9FG_ "S>X^:H%-E*G =*AW2 3/5^*64#
M*_; \:=72+$P0=&G$X\YQ#GD=Z%_/[)]LH<O4ZKCMPS@,&X9H\F=WD**:'2L
M--I;*#G&R113.*[=%^V.4BP?(H4 $H_9;-N=:]A6JVKHFM27U.%6O$@8DC )
M]'&*[<]E7&O:2VVC0I,L93Y<HC]^SS^I-_H=C /_ #-B _$9'?5R7YDMGJ4D
MOU1"PA*925^$ #A&N&P;ZE(2#E_%/QBIO;S>I*4!,-0Q?L'CMDZ&\/B/5( Z
M!KJOS(;%6G2I]2TG-("A/LF4R$?#T_OJL'%?L^/=.7MB0V'?;0<K+/+LCYDR
MKBW&5?!9)1\%<7D+Q9_I2G+YI6+9)HPB"+*$W*!CN! !U5K_ .9>S+IC3[?I
MW?$(^]X@$O3W1[HW-HZ;.^,'7G4 <M)^,-&<&/39XX\"JFYB\0PRTE=)M!%&
MX92LQ$'ETLYDBC^85<E+Y47%D,8#$:M]DP,4!,)AW'2P;LWMN'=S_B7-TZ0)
M!,R0!.8S.>?P@KVRP4%J'<2%.R^]*43Q<123MHNT?)MW;9RBL@Z072\Y%R@N
MD=)=-PFL)R+$634,4Q3 )!*.PAMJG@NLA*J,Z'DD&?:#/A(QL33AY2A4'4V1
M(#E[85AYU>W%A<@V^;R;P^O4#CMY8';F1F<475)Y^J99!XJHZ64J\\U(Z=0S
M=1P<1(T42421 PE(8"]-,CL?KS66.A30;B2X\V)#6%RPXS!F9^B!ON#8#=8O
MQ67$#LT^Z<X$\Y]O'ZD*3A5%&KXJ>(IF[2.D<F1J::WVF*FX;)JE#ITW -]&
M2G\R&PVV4IDA"I8ZP5S]$DB7;%/J-@53ND,IP3.?=SCC#V\GJ2B&_P"J&+P_
M\SH?_HM3_P"I/8?Z=/\ _J5\(QOW=7+]$_JF*?L\WJ2[=:=C$ V^&2XH1 1^
M/5 H &_CU\-1M>9':C+A<6ZI<\@-0^M,1*Z?;E+(9#H$C^@?C#%_H;<!^0W!
MJC9^KF?HJMQ$E?[94Y>MGK=B9V1%9A$0S^.?'75:E(#5PF\.4 (8![BCOI;.
MKN^[;O>OIJRU.:D-J7K209@*E+$R^@@K;(MUQM-,NDK\9)$C*4^!PB>/-[TY
M./'/2G-J[F. ^FL<&@J2EY)KA$V-VJ"RAC* 1D]/WH2$0*VRAV#DBC<Y_F "
MFV-JB[4WKN7:5R^:MS__ "),RSB HCF0??*-Q>MNT=X1I,D*YRG\(5LS+[9O
ME16)AZ.$\N8QRC6DUC&8$LQG=$L_DB(]B+YL1K(0*JQ0V^<BY.N_AIFK1YE=
MN+ 3<*=YMT :N^")\9223[8%=TZ:7@$FF?043P&@Y</Q1'4?;R^I)WB4*AC
M0 1^<,F1 D, =.@@D([C^YJWJ\Q^S$,ZJ<K0X<..7ZHC54NRK\DEIQ,TR..D
M_&*#[>/U)=P_S2Q:  8#")LFQ8#\N_;L MNHF$=OAMK7W#S$[4KK>JB\525J
M_$=4AZM,24FQ=P4E1XP5-,\M)^,2*Y+^AASZRGFVZWRI5;'RM?G4ZL+!5_D"
M*9.1/&5&OPSXBR!RF,D*3V,5 !'[Q=A^.JKMOK5MRT606QU*G%AY2]8.!Q'#
M23C+GQB6MV3>;G5$D:>]F1_##/OI=<?<C\7.%&'<&Y89QS&^TTEG_3B$/(H2
M\4096USDLQ^DDFX@FZ*>/=I',( ':)^T>H:7/J??F=T[DJ;O;OV?CK24I)F9
M S,\!P@P[7MK]HMR:)X:I#[V0]F/*,8>KKAGEMR/XWEP'Q5B8!4V1)@$,K3D
MY;&U6,UHT:D5V%?C3N ,+M:SR?EI+  ; @F8!^]K)V+<K/:+JU<KT0$M%) [
M>>1RE$&X:2HJJ%RDI\%K!QY<,H6JPA[>SF:\RYCY'-D;1('$R=GC%LART'>H
MZ5EB5ALHFO+,HY@W2!=5X_00^G*(;>7YPG*/33-WGS";2:L=6S0)4JX.L!+*
MM4O#(1IGBG$$R,@1R@6;?V)76]P?-+#AUDDZ2,U3EF<LH>*K-7BJI P]<@&K
M>+A(1BRBH6-9HE0:QT9'-46+!DW1*(%30:L4")%*&P;%W\=QTEK;JZFI=KZA
M0=J'5J45Y3U&?&<'&@8-,R$#[@&4>A6:BJ7M*?M#O QN@]0#J ^/WBF !#4C
M92A96H3,9#(2RI1EG +O6E],BW<Z*?CNVX2;P 9VQV^<190F7S>#9V''\P4R
MC]@ZDW!3I%=PT@D"[0H@(#YRA? =%WI)U.MFQ;P\W>0IRC>;[J J6E1F-6(.
M>'#A%$W/M-=U:4^W(NY3E BN$?I,^J+PWY,8PSQ 53':S*L2Z+*Z0K;*$60+
M)19-0&MDACD!, 754C5!41 VX Y2(;X!HB[UZH;/W3MU^U53RG'B%*:P4"E6
M:!B.8 BF;=VY>[17(!05,^(F9E(2GC[H=#^I/_DP_P#8/J?[^A]__)OO^/\
..RGW/PZ5KO>[WP;I1_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
